Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

FoundationOne

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

- PMLiVE

Enhertu to provide patients with vital targeted therapy option

Therapy receives FDA priority review as patients with HER2-mutant metastatic non-small cell lung cancer seek alternative treatment

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

The two companies will withdraw patent infringement proceedings filed with the US and Japan

- PMLiVE

MHRA grants approval for AstraZeneca’s Evusheld in the UK

It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

- PMLiVE

Ovarian Cancer Commitment announced to improve patient care

The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

Research Partnership

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links